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Pancreatic invasive ductal adenocarcinoma (PDAC) is a representative intractable malignancy under the current cancer therapies, and
is considered a scirrhous carcinoma because it develops dense stroma. Both PODXL1, a member of CD34 family molecules, and
C5aR, a critical cell motility inducer, have gained recent attention, as their expression was reported to correlate with poor prognosis
for patients with diverse origins including PDAC; however, previous studies reported independently on their respective biological
significance. Here we demonstrate that PODXL1 is essential for metastasis of PDAC cells through its specific interaction with
C5aR. In vitro assay demonstrated that PODXL1 bound to C5aR, which stabilized C5aR protein and recruited it to cancer cell
plasma membranes to receive C5a, an inflammatory chemoattractant factor. PODXL1 knockout in PDAC cells abrogated their
metastatic property in vivo, emulating the liver metastatic mouse model treated with antiC5a neutralizing antibody. In molecular
studies, PODXL1 triggered EMT on PDAC cells in response to stimulation by C5a, corroborating PODXL1 involvement in PDAC
cellular invasive properties via specific interaction with the C5aR/C5a axis. Confirming the molecular assays, histological examina-
tion showed coexpression of PODXL1 and C5aR at the invasive front of primary cancer nests as well as in liver metastatic foci of
PDAC both in the mouse metastasis model and patient tissues. Hence, the novel direct interaction between PODXL1 and the
C5aR/C5a axis may provide a better integrated understanding of PDAC biological characteristics including its tumor microenviron-
ment factors.
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Introduction
Invasive ductal adenocarcinoma of the pancreas (PDAC) is the most
common pancreatic malignancy and has been recently highlighted as a
serious issue for cancer treatment, given persistent clinical intractability
to known therapeutic countermeasures aimed at improving patient prog-
nosis [1,2]. PDAC shows unique histology, where proliferating cancer
nests are surrounded by abundant collagenous stroma with
cancerassociated fibroblasts (CAFs), inflammatory cells such as macro-
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phages and lymphocytes, and scanty tumor blood vessels from neovascu-
larization. These stromal components form a so called tumor microenvi-
ronment essential to cancer progression in vivo. Hence, tumor
microenvironments are complex systems of various cellular components,
observed to release diverse inflammatory chemokines that interact with
cancer cells resulting in tumor growth, invasion and metastasis.
Podocalyxinlike 1 (PODXL1), is an antiadhesive sialomucin, belonging
to a member of the CD34 family harboring the extracellular domain and
intracellular domain via the transmembrane portion. It is expressed by
normal vascular endothelium, renal podocyte, and hematopoietic progen-
itors [3–5] and has been reported to be a stem cell marker including
embryonic stem cells [6,7]. Noticeably, there have been studies demon-
strating correlation between PODXL1 expression and poor prognosis of
patients with cancer of the diverse origins including colorectal cancer
[8], gastric cancer [9], and pancreatic cancer [10]. Functionally, PODXL1
was reported to promote invadepodia formation and metastasis through
Rac1/Cdc42/cortactin signaling in breast cancer cells [11], to induce col-
lective migration of MCF7 cells depending on activity of the actin scaf-
folding cytoplasmic protein ezrin [12]. Recently, it was revealed that
PODXL1 was involved in efficient EMT extravasating via the Ezrin signal-
ing on breast cancer and pancreatic cancer cells [13]. Hence, PODXL1
appears critically involved in causing invasion and metastasis of various
cancers and is one of the most important regulators of human malignan-
cies; however, the diverse biological roles of PODXL1 still require elucida-
tion for generating future cancer therapeutics. On the other hand,
multiple chemokines have been reported as produced in tumor microen-
vironment in response to inflammatory reaction and tumor immunity
against cancer cells. Among them, C5a, a soluble complement which is
related to inflammatory reaction and chemotactic response, has been
reported to promote tumor development and progression including cellu-
lar motility and invasion, and its expression was related to poor prognosis
in PDAC patients, on account of interaction with Gproteincoupled com-
plement receptor, C5a receptor (C5aR; CD88) [14–17]. Thus the
C5aC5aR interaction in cancer stroma has been recently highlighted as
a key accelerator of cancer metastasis in tumors with diverse origins, such
as breast, lung and gastric cancers [14–17].
Here, we demonstrated the novel function of PODXL1 capture of a
key metastatic regulator, C5aR, in the PDAC microenvironment, to stabi-
lize and activate it as specific binding partner, triggering PDAC invasion
and metastasis by accelerating tumor cell motility through activation of
the C5aR/C5a axis.
Materials and methods
Cell culture and antibodies
Human PDAC lines, BxPC3 (ATCC: CRL1687), AsPC1 (ATCC:
CRL1682), MiaPaCa2 (ATCC: CRMCRL1420), Panc1 (ATCC:
CRL1469), an immortalized nonneopastic pancreatic ductal cell, HPNE
(ATCC: CRL4023), normal human dermal fibroblast, NHDF (ATCC:
PCS201010) were grown in RPMI1640 (Wako, Tokyo, Japan) supple-
mented with 10% of fetal bovine serum (FBS) in a 5% CO2 incubator.
Authentication of each cell line was attached. Antibodies employed in this
study were as follows. As a primary antibody, antiPODXL1
(SigmaAldrich, Merk, St. Louis, MO), antiIntegrin 1 (Invitrogen, Thermo
Fisher Scientific KK, Japan), antiC5aR (CD88) (Hycult Biotech, Wayne,
PA), antiC5a (R&D Systems, Mineapollice, MN), antiMyctag
(SigmaAldrich), antiFLAGtag (Invitrogen, Thermo Fisher Scientific
KK), antiTubulin (CST Japan, Tokyo, Japan), antiECadherin (Invitrogen,
Thermo Fisher Scientific KK), antiSnail (CST Japan), antiVimentin (CST
Japan), antiTRA160 (CST Japan). As a secondary antibody,
Alexa488conjugated goat antimouse IgG(H + L), Alexa488goat
antimouse IgM, Alexa555goat antimouse IgG(H + L), Alexa488goat
antirabbit IgG(H + L), Alexa555goat antirabbit IgG(H + L),
Alexa555donkey antigoat IgG(H + L), HRPconjugated goat antimouse
IgG(H + L), HRPgoat antirabbit IgG(H + L) (for all of these: Invitrogen,
Thermo Fisher Scientific KK) were used for the immunohistochemistry,
immunofluorescence and immunoblot assays.
Patients tissues, immunohistochemistry and immunofluorescence
Paraffinembedded surgical specimens fixed with 10% bufferedformalin
and made from the patient tissues of the pancreatic invasive ductal adeno-
carcinoma were obtained from the department of pathology, Niigata Can-
cer Center Hospital under approval by the ethics committees of Niigata
University and Niigata Cancer Center. Ten cases of primary PDAC tissues
(well differentiated; 3 cases, moderately differentiated; 4 case, poorly dif-
ferentiated; 3 cases) and four cases of liver metastasis of the corresponding
PDAC from the same individual among these ten patients were examined
for expression for the proteins of the interest by immunohistochemistry
and immunofluorescence, using antiPODXL1, antiC5aR, and antiC5a,
antiTRA160 antibodies. All specimens were autoclaved prior to incuba-
tion with the primary antibody (at 4 celcius for 12hours) for immunohis-
tochemistry or immunofluorescence.
Plasmid construction for a panel assay of the chemokine receptors
For the panel screening of chemokine receptors as a binding partner of
PODXL1, the plasmids encoding, in total, forty human chemokine recep-
tor were constructed, respectively. These were contransfected with human
PODXL1 and subjected to immunoprecipitation assay. In detail, for the
expressor plasmid construction, cDNAs of interest were subcloned into
the pIDTSMART (CTSC) vector to obtain efficient gene expression in
a transient manner [18]. The prepared cDNAs covering the entire ORF
were as follows: human cDNAs encoding PODXL1 (transcript variant 1;
GenBank NM_001018111) and chemokine receptors (C3aR, C5aR,
CXCR16, CX3CR1, XCR1, CCR111, BLT1, 2, LTR1,2, EP14, DP1,2,
FP, IP, TP, and LPAR16). PODXL1 was designed to express as a
Cterminal 3xMyc6xHistagged form. Chemokine receptors were all
designed to express as Cterminal 3xFlag6xHistagged forms.
Immunoblot and immunoprecipitation
All immunoblot analyses were performed with the cell lysates prepared
with MPER mammalian protein extraction reagent (Thermo Fisher Scien-
tific) under standard conditions using each of the specific antibodies men-
tioned above. For the coimmunoprecipitation assay, HEK293T cells were
transiently transfected with the PODXL1 expressor (PODXL1 with
3xMyc6xHistagged at the Cterminal end). Chemokine receptors were
all designed to express as Cterminal 3xFlag6xHistagged forms. Combined
with a series of chemokine receptorexpressors mentioned above using
FuGENEHD (Promega), respectively. Twentyfour hours
postcotransfection, cell pellets were harvested and lysed in MPER buffer.
The prepared lysates were then incubated with agarose beads conjugated
with monoclonal antiMyc tag antibody (MBL, Nagoya, Japan). The resul-
tant immunoprecipitates were subjected to immunoblot probed with
antiFlag tag antibody. To examine direct binding between PODXL1
and C5aR, PODXL1 was purified from the cell lysate of the PODXL1-
HA(x3)His(x6)tagged expressortransfected HEK293T cells using
antiHistag antibodyconjugated beads (#D2918; antiHistag mABagarose
beads; MBL Co. Ltd., Japan). C5aR protein was also isolated from the
lysate of the C5aRFlag(x3)His(x6)tagged expressortransfected 293 T cells
using antiHistag mAb beads. Each protein was mixed together, incubated
for 30 min at RT, then the sample was precipitated using beads conju-
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gated with antiHAtag antibody (#5618; antiHAtag pAbagarose beads;
MBL Co. Ltd., Japan) for pulldown of PODXL1. The pulldown sample
was subjected to SDSPAGE, blotted onto membrane after fractioned, and
immunoblotting with antiHA antibody (#3724; HATag C29F4; Cell Sig-
naling Technology, Danvers, MA) or with antiFlag antibody (#F1804;
antiFlag M2 mAb; Sigma Aldrich Japan, Tokyo, Japan) was performed,
respectively. As a control, purified PODXL1HAHis alone and
PODXL1HAHis incubated with heatdegraded C5aRFlagHis protein were
employed.
Generation of PODXL1/ clones by the CRISPR/Cas9 system
PODXL1knockout PDAC cell lines (for MIaPaCa2, AsPC1, and
Panc1) were generated using CRISPR/Cas9 system. Both plasmids, hCas9
(#41815 Addgene, Watertown, MA), and gRNA (guide RNA) Cloning
Vector (#41824), were obtained from Addgene. The gRNA vector includ-
ing PODXL1 target sequence (CGACACGATGCGCTGCGCGCtgg)
located in part of the Exon 1 was prepared following the manufacturers
instruction with tgg sequence as a Protospacer Adjacent Motif (PAM).
The hCas9 and PODXL1 gRNA vector were cotransfected into cells using
ViaFect Transfection Reagent (#E4981, Promega, Madison, WI).
Twentyfour hours posttransfection, the cells were cultured with RPMI
medium containing 500 g/ml of Geneticin (#1013135, Gibco, Thermo
Fisher Scientific, Waltham, MA) for isolating the Geneticinresistant
clones. PODXL1expression deficient clones from each PDAC line were
confirmed by lack of PODXL1 protein, using immunoblot analysis with
antiPODXL1 antibody. Genetic mutation of PODXL1 in the knockout
clone was also examined by genomic DNA sequencing of PCRamplified
product, using the specific primers for PODXL1target sequence and the
adjacent genomic DNA. The primers used for the sequencing were the fol-
lowing: Pod1.Ex1.check.Fw2: 5CAGCGGCAGGGAGGAAGAGC and
Pod1.Ex1.check.Rv2 5GCGGTGCGGTCTCCCTTTTCTT.
Image based protein–protein interaction (PPI) analysis (Fluoppi assay)
The proteinprotein interaction between PODXL1 and candidate pro-
teins (EP4, CXCR2, C5AR, LTB4R, CTTN and CXCR1) was detected
using the FluoPPI system (MBL, Nagoya, Japan), in which PPIs were
visualized as fluorescent foci [19,20]. PODXL1 was subcloned into a
pAshMNL ver.2 plasmid to fuse with an Ash (homo oligomerized protein
assembly helper) tag (PODXL1Ash). Candidates were subcloned into a
pMontiRedMNL plasmid to fuse with a MontiRed (homo tetramer red
fluorescent protein from Montipora sp.) tag (CTNNred or C5aRred).
These plasmids of PODXL1Ash and candidatesRed were cotransfected
into HeLa cells using Lipofectamine 3000 (Thermo Fisher Scientific, Wal-
tham, MA, USA) according to the manufacturers instructions, respec-
tively, and intracellular fluorescent foci with red color were observed by
inverted fluorescence microscope (Olympus IX71, Olympus Co. Tokyo,
Japan) and detected as an image using cellSens imaging software (Olym-
pus Co.).
Invasion assay
Cells were starved by serum free medium for 24 h prior to invasion and
migration assays. Cell invasion and migration assays were both evaluated
by the Boyden chamber method using the filter inserts (pore size, 8 m),
precoated (for invasion assay) or not precoated (for migration assay) with
Matrigel in 24well plates (BD Biosciences, Franklin Lakes, NJ, USA).
Each pancreatic cancer cell line (7.5 104 cells/insert for MIA PaCa2,
2 105 cells/insert for AsPC1, or 4 104 cells/insert for PANC1) was seeded
on the top chamber. The top chamber was filled with serumfree medium
and the bottom chamber was filled with 10% FBS medium. The recom-
binant chemokines were then set in the bottom chamber at a final concen-
tration of 25 ng/ml for CXCL8 (PeproTech, Rocky Hill, NJ, USA), and
0.5 M for PGE2, 5 ng/mL for CX3CL1 (R&D Systems, Minneapolis,
MN, USA) and C5a (ProSpecTany Technology Ltd, Ness Ziona, Israel).
After incubation for 8 h in the case of PANC1, or 48 h in the case of MIA
PaCa2 and AsPC1cells, cells that passed through the filter and were
attached to the lower surface of the filter were counted by staining with
0.01% crystal violet in 25% methanol. Cells attached to the lower surface
of the filter membrane were then quantified by cell counting in five
nonoverlapping fields at 100 magnification.
RNA interference assay using siRNA
Predesigned siRNAs for human C5aR (ID D00544200005) and con-
trol siRNA (ID D0018101005) were purchased from Dharmacon (Lafay-
ette, Colorado, USA). siRNAs (final concentration 50 nM) were
transfected using Lipofectamin RNAiMAX reagent (Thermo Fisher Scien-
tific). Fortyeight hours postintroduction of each siRNA, the cells were
subjected to the invasion assay described above.
In vivo mouse liver metastasis model
1 106 cells of MiaPaCa2, AsPC1, or Panc1 were injected into
6 weekold nude mouse spleen exteriorized through a left flank incision,
respectively, followed by splenectomy 2 min later. The same number of
the PODXL1/ PDAC cells corresponding to each cell line were injected
in the same way with the same timing. Approximately 30 days
postinjection, the mice grew metastatic liver tumors derived from the
injected PDAC cells, and they were then autopsied and compared for
tumor formation pairwise with the mice implanted with PODXL1/ cells
under the stereo microscope. Total number of mice examined in each
group was four (n = 4). Only in the case of Panc1 splenic xenograft, num-
ber of mouse examined was two (n = 2). In the C5a blocking assay, each
mouse with splenic injection of 1 106 of MiaPaCa2 cells was treated with
intravenously administrated 50 g/mouse of antiC5a neutralizing antibody
on Day 0 (the day of cellimplant), Day 7, Day 14 (in total three times, and
once every week), and autopsied and examined on Day 30 pairwise with
mice (control group) treated with the same dose of goatIgG. Totally, four
mice (n = 4) were examined in each group. Excised tumors in all animal
experiments were histologically examined with paraffinembedded speci-
mens by HE staining and immunohistochemistry using antihuman cytok-
eratin, CAM5.2 (BD Biosciences, San Jose, CA) to demonstrate human
PDAC cells (MiaPaCa2, AsPC1, and Panc1, respectively) origin.
Statistical analysis of metastatic tumors in mouse models
Based on macroscopic finding in combination with microscopic exam-
ination of the tissue specimens, number of liver metastasis was counted in
each group of mouse splenically injected with MiaPaCa2, AsPC1 in every
animal experiment. Average number of metastasis per liver in each case
was statistically evaluated by ttest (shown as graph with P value).
Results
Characteristic expression of PODXL1 on human PDAC tissues
PODXL1 expression on PDAC tissues has been reported in previous
studies that demonstrated PODXL1 preferentially expressed on the cancer
nests in comparison with the nonneoplastic pancreatic acinus and duct,
with the expression correlating to the patients poor prognosis [21].
Immunohistochemistry on representative primary PDAC patient tissues
using antiPODXL1 antibody revealed that strong membranous PODXL1
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expression with or without cytoplasmic expression was observed mainly at
the small collective cell formingcancer nests at the invasive front of the
PDAC tumor in examined cases (1; well differentiated type, 2,3; moder-
ately differentiated type, 4; poorly differentiated type, respectively) (Fig-
ure 1A), but a small number of strong PODXL1positive cancer cells
were observed among the individual tumor glands adjacent to the small
invasive nests (Supplementary Figure S1A). PODXL1 expression was
not dependent on the differentiation type of PDAC but was detected in
all types examined. It has been also reported that the glycosylated form
of PODXL1 was recognized as TRA160 antigen [22], an embryonic stem
cell and iPS cell marker. TRA160 expression was detected in similar pat-
terns to that of PODXL1, where TRA160 was strongly positive in small
cancer nests at invasive foci in PDAC patient tissues under immunohisto-
chemistry (Supplementary Figure S1B, upper panel) Immunofluorescence
using antiPODXL1 and antiITGB1 (Integrin 1, CD29) antibodies high-
lighted the budding tumor cell from the neoplastic gland acquiring strong
expression of PODXL1 as well as ITGB1, indicating PODXL1 might be
required for epithelialmesenchymal transition (EMT) of the PDAC cells
(Figure 1B and Supplementary Figure S1B, lower panel). Accordingly,
the budding single PDAC cell was also detected by immunofluorescence
using TRA160 antibody (Supplementary Figure S1B, lower panel). The
robust expression of PODXL1 was also observed not only in PDAC but
also various cancers, as for example, its expression on invasive nests of col-
orectal tubular adenocarcinomas (Supplementary Figure S1C).
PODXL1 is critically involved in metastasis of PDAC cells in vivo
To elucidate the biological role of PODXL1 in PDAC cells in vivo,
generation of PODXL1targeted PDAC cell clones was achieved by using
the CRISPR/Cas9 genome editing system. First, endogenous expression of
PODXL1 was examined in four different human PDAC lines established
from different patients. As nonneoplastic counterparts, human immortal-
ized pancreatic ductal epithelium (HPNE) and normal kidney epithelial
cells were also examined for its expression. Consequently, all four PDAC
lines showed strong expression of PODXL1 including the supershifted
(hyperglycosylated) form (Figure 2A), and HPNE showed comparably
weak PODXL1 expression with a similar pattern, but the glycosylated
form was not detected in kidney cells (Figure 2A). These PDAC lines
showed membranous expression of PODXL1 as well as its cytoplasmic
expression (Figure 2B, upper panel), representing lamellipodia and plasma
membrane localization in AsPC1 and MiaPaCa2 cells (Figure 2B, lower
panel). Based on this finding, genome editing to knockout PODXL1,
including variant 1 and 2, was performed using the CRISPR/Cas9 system
with the designed guideRNA (gRNA) recognizing the part of the exon 1
both on MiaPaCa2 and AsPC1, respectively (Figure 2C, left panel). Four
respective PODXL1/ (PODXL1KO) clones were obtained both in
MiaPaCa2 (clone #3, 9, 15, 37) and AsPC1 (clone #2, 3, 9, 13), all of
which were confirmed as to specific impairment of PODXL1, utilizing
immunoblots and genome sequencing (Figure 2C, right panel and Supple-
mentary Figure S2A). Using these knockout (KO) clones, the murine pan-
creatic tumor model of liver metastases was established by hemispleen
injection of the MiaPaCa2 cells lacking PODXL1 expression (KO clone
#9) and AsPC1 PODXL1KO cells (KO clone #2), and by using the wild
type MiaPaCa2 and AsPC1 cells for comparison, respectively. After
30 days postinjection, the wild type MiaPaCa2implanted mice developed
multiple metastatic foci in the liver, whereas no metastatic foci were
observed in the mice implanted with the PODXL1KO #9 clone (Fig-
ure 2D, upper panel). Similarly, loss of liver metastasis was observed in
mice injected with the AsPC1 PODXL1KO #2 clone in contrast to the
cases with the wild type cell injection (Figure 2D, lower panel). Number
of the intrahepatic metastasis per liver between group of implanted PDAC
cells bearing PODXL1 wild type and those of PODXL1knockout (n = 4 in
each group) was summarized in graph which showed statistical significance
(Figure 2D). Similarly, loss of mesenteric lymph nodal metastasis was also
observed in the mice treated with the KO clone of MiaPaCa2 (n = 4 in
each group, Supplementary Figure S2B), and the PODXL1KO clone of
Panc1 PDAC cell showed the similar phenomenon (Supplementary Fig-
ure S2C). Histological examination of the intrahepatic and lymph nodal
metastatic tumors demonstrated that metastatic tumors were derived from
hemisplenically injected human PDAC cells in the mice treated with
tumor cells bearing PODXL1 wild type, and no micrometastatic lesion
was observed even microscopically in the liver of the mice injected with
tumor cells harboring PODXL1knockout (Supplementary Figure S3A,
3B, and 3C).
PODXL1 captures diverse chemokine receptors including C5aR
The next issue determined was how PODXL1 is critically involved in
PDAC invasion/metastasis. Recently, the tumor microenvironment has
received much attention because many current studies reveal its significant
impact on cancer progression in terms of tumor growth, invasion and
metastasis. The tumor microenvironment is a complex system comprised
of fibrous stroma, tumor angiogenesis, tumor immunity and inflammatory
reaction. Among these, we focused on chemokine receptors which affect
the chemotactic cellular motility through interaction with soluble inflam-
matory chemotactic ligands in the tumor microenvironment. A panel
screening for over forty chemokines was performed to find the specific
association between PODXL1 and these molecules by employing
immunoprecipitation. The results showed that PODXL1 bound multiple
chemokine receptors such as C5aR (C5aR1), CXCR1, CXCR2, CXCR3,
CXCR4, CXCR6, CX3CR1, CCR1, CCR3, CCR8, CCR9, BLT1,
BLT2, EP2, EP4, DP1, DP2, FP, IP, LPAR1, LPAR2, LPAR4, LPAR5,
and LPAR6 (Figure 3A). Among these, we further examined expression of
selected chemokine genes semiquantitatively by RTPCR, which revealed
enhanced coupling to PODXL1. Essentially all selected chemokines were
more or less expressed on PDAC cells and C5aR receptor was the strongest
and most consistently expressed on them (Figure 3B). Prominent mem-
branous C5aR expression was detected on all five representative PDAC
lines, BxPC3, PK8, Panc1, MiaPaCa2, and AsPC1 (Figure 3C).
PODXL1 accelerates cellular motility by regulating functional
localization and stabilizing C5aR, and triggers EMT via the C5aR/
C5a axis on PDAC cells
Based on these results, the biological role for protein coupling of
PODXL1 and C5aR was investigated on PDAC cells bearing the wild type
PODXL1, compared with the PODXL1KO cells. Confirmed specific bind-
ing of PODXL1 to C5aR was observed only in wild type PODXL1
(PODXL1WT) MIaPaCa2 cells but not in the PODXL1KO cells (Fig-
ure 4A); intracellular localization of C5aR was examined with or without
PODXL1 as to whether or not this would be affected by the presence of
PODXL1. In image based protein–protein interaction (PPI) analysis, the
so called Fluoppi system, aggregated fluorescent dots appears only when
two proteins of the interest directly binds to each other. Based on the
result of Fluoppi analysis using HeLa cells, C5aR was successfully
recruited to lamellipodia at the cell membrane on the PODXL1-
cotransfected cells which was recognized as aggregated red dots, as in
the case of Cortactin (CTNN)PODXL1 cotransfected cells (Figure 4B
and Supplementary Figure S4A). On the other hand, it was still retained
at the cytoplasm without PODXL1 expression (only with pAsh) (Fig-
ure 4B). Other chemokine receptors, such as EP4 and CX3CR1 seen as
candidate binding partner to PODXL1, also displayed changes in intracel-
lular localization to their functional site in the presence of PODXL1 (Sup-
plementary Figure S4B). Thus, PODXL1 appeared essential for targeting
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C5aR to its functional site by cellular assay. Direct coupling between
PODXL1 and C5aR was also demonstrated by pulldown assay using
antiHAconjugated beads to isolate binding partner of 3xHA6xHistagged
PODXL1 protein (Supplementary Figure S4C). Based on the immuno-
precipitation assay results – establishing the diverse chemokine receptors
as binding partner with PODXL1 – CXCL8 (ligand to CXCR2),
CX3CL1 (ligand to CX3CR1), C5a (ligand to C5aR), and PEG2 (ligand
to EP4), all of which showed augmented association, were incubated with
MiaPaCa2 cells and quantified for the increase in cellular motility, using
transwellchamber assay (Boyden chamber assay), between the PODXL1-
WT and the PODXL1KO cells. The data indicated that the ligand stim-
ulation by C5a robustly increased PODXL1WT MiaPaCa2 cellular
motility in comparison with that of C5astimulated PODXL1KO clone
(Figure 4C). This phenomenon was specific because the MiaPaCa2 cells
treated with C5aR siRNA markedly decreased the cellular motility even
when incubating with C5a (Supplementary Figure S4A). The response
to C5a seemed to be common to the other PDAC cells such as AsPC1
and Panc1 (Supplementary Figure S4B). We found that another feature
of PODXL1C5aR interaction was the pronounced attenuation of C5aR
expression in the PODXL1KO PDAC cells. In the immunofluorescence
results, C5aR expression was much weaker in PODXL1KO MiaPaCa2
and AsPC1 in contrast to the PODXL1WT cells, and we made similar
observations for PODXL1deficient Panc1 cells (Figure 4D and Supple-
mentary Figure S6A). Total protein for C5aR was examined by immuno-
blot using antiC5aR antibody, and its comparative reduction in the
PODXL1deficient cell was corroborated, using whole cell lysates, between
Figure 1. Expression of PODXL1 on human PDAC tissues from the patients. (A) IHC using anti-PODXL1 Ab on well differentiated type (1),
moderately differentiated type (2, 3), and poorly differentiated type PDAC (4). Hatched box indicates the area for hyperview in each case (4, 20, 60). (B)
Double IF using anti-PODXL1 Ab (red) and ITGB1 (green) (left panel). Schematic representation of the PODXL1-expressing budding cancer cells from
the tumor gland were highlighted.
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Figure 2. Loss of liver metastasis in the PODXL1-deficient PDAC cells in vivo. (A) endogenous PODXL1 expression in six PDAC lines (BxPC3, PK-8,
Panc-1, MiaPaCa-2 and PL45), HPNE and kidney epithelial cells as a non-neoplastic by IB using anti-PODXL1 Ab. Note the glycosylated form of
PODXL1 showed as supershifted. (B) Expression of PODXL1 detected by IF. Hyperview of AsPC-1 and MiaPaCa-2 showed expression of PODXL1 at
the surface membrane as well as at the cytoplasm. (C) Schematic representation of the guide RNA design for the knockout, recognizing a part of the exon
3 (black box) within the PODXL1 genome (left). Confirmation of the KO clones of MiaPaCa-2 (#3, #9, #15, #37) and AsPC-1(#2, #3, #9, #13) by IB
using anti-PODXL1 Ab. The 293T lysate transfected with HA-tagged ful-length PODXL1 variant 1 was used as a positive control. a--tubulin indicated
the IB using anti-total tubulin Ab. (D) Development of liver metastasis 30 days after splenic injection of the PODXL1-WT or the KO cells in Balb/c nu/
nu mice (n = 4 in each group). Attached Graphs showed average number of liver metastasis/mouse in MiaPaCa-2-injected or AsPC-1-injected mice
(n = 4/each WT or KO group, means and s.d. of quadruplicate were shown).
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the WT cells and the KO cells, in MiaPaCa2 and AsPC1, respectively
(Figure 4E, left panel). Furthermore, immunoblot of the cellular fraction
revealed that the majority of C5aR was detected in the membrane fraction
of PODXL1WT AsPC1 and MiaPaCa2 cells, respectively, while in the
PODXL1KO cells the majority of C5aR was contained in the cytosol frac-
tion (Figure 4E, right panel). These results implied that lack of PODXL1
might impair the protein stability and the functional localization of C5aR
in PDAC cells. Given the aggregate findings, we examined whether the
PODXL1C5aR interaction was involved in EMT of PDAC cells. Total
cell lysates were prepared from each PDAC cell sample with or without
C5a stimulation for 12 hours in the PODXL1WT and the KO phenotype
of AsPC1 and MiaPaCa2. The sample from the C5atreated PODXL1WT
cells showed marked reduction of ECadherin in contrast to an increase in
Snail and Vimentin, whereas the KO phenotype displayed no significant
quantitative fluctuations of these proteins (Figure 4F). The
PODXL1C5aR/C5a axis was therefore demonstrated to be one of the crit-
ical pathways for triggering EMT of the PDAC cells.
Significance of C5aR/C5a axis for the PDAC metastasis in the
presence of PODXL1 in vivo
With the specific interaction of PODXL1 and C5aR in PDAC cells
thus confirmed, the biological impact of C5aR/C5a signaling for promot-
Figure 3. PODXL1 captures multiple chemokine receptors. (A) Panel screening of the forty chemokine receptors as a binding partner to PODXL1. Pull-
down assay (IP) using anti-myc tag Ab for the lysates from the myc-tagged PODXL1-cotransfected 293T with each Flag-tagged chemokine receptor gene
detected the specific binding partner to PODXL1. IB was performed by probing with anti-Flag Ab for the precipitates. (B) Expression of the each
chemokine receptor that showed binding affinity to PODXL1 in Figure 3a was examined by RT-PCR among five PDAC lines, NHDF (fibroblast), A549
and PC9 (both lung adenocarcinoma lines). (C) IF using anti-C5aR Ab revealed membranous expression of C5aR on PDAC cells.
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ing PDAC metastasis was examined using the experimental PDAC liver
metastasis model in nude mice. Animals injected in the spleen with
1 106 of MiaPaCa2 cells were either treated three times, in total, with
antiC5a neutralizing antibody (50 g/every 7 days), or with the same dose
of goat IgG as a control following the schedule shown in Figure 5A. Thirty
days after splenic injection of MiaPaCa2 cells, mice were freshly autopsied
and examined for liver metastasis. Significant differences were thereby
observed in number of metastatic tumor foci (representative histology
for these metastatic tumors was shown in Supplementary Figure S6B) as
shown in the stereoscopic image and the summarized graph, where the
neutralizing antibodytreated mice were poorly showing in metastatic foci
(Figure 5A). Thus, the activation of C5aR/C5a signal significantly con-
tributed to liver metastasis formation of PDAC cells in vivo. Immunohis-
tochemistry indicated that metastatic cancer cells were positive for C5a,
C5aR, and PODXL1 (murine hepatocytes were also positive for C5a
and C5aR), and immunofluorescence revealed the coexpression of
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PODXL1 and Vimentin as an EMT marker on cancer cells at the meta-
static foci (Figure 5B).
Detection of C5aR, C5a and PODXL1 in human PDAC patient
primary tissues and liver metastatisis
Since the interaction between PODXL1 and C5aR/C5a axis was estab-
lished in the mouse PDACxenografted model, we then investigated the
endogenous expression of these molecules in human patient tissues. Strong
C5aR expression was detected on the invasive nests of primary PDAC tis-
sues as well as PODXL1 expression (Figure 6A), and the merged image of
double immunofluorescence detecting PODXL1 and C5aR displayed a
few double positive cells inside the invasive cancer nest with membranous
colocalization (Figure 6B). In liver metastasis from the same PDAC
patient, C5aR and PODXL1 were consistently expressed on the same
individual cancer cells as well as in the primary site (Figure 6C), and
C5a, as a ligand to C5aR, was strongly positive both on nonneoplastic
hepatocytes (Figure 6D, upper panel) and metastatic PDAC cells (Fig-
ure 6D, lower panel, hyperview). C5aR expression was also maintained
at the lymph nodal metastasis of PDAC (Supplementary Figure S7).
Discussion
In previous studies, expression of PODXL1 had been reported to
reflect adverse prognosis for the patient with diverse cancer origins includ-
ing breast, colorectal, gastric, and pancreatic adenocarcinoma [4,8–10,23].
Similarly, C5aR/C5a expression is known to correlate with clinical prog-
nosis for various lineages of cancer [14,16,17]. Moreover, both PODXL1
signaling and C5aR/C5a signaling were proven molecularly to facilitate
tumor cell invasion in vitro by activating specific kinases [13,24,25]. For
example, PODXL1 triggers invasion by increased matrix metallopro-
teinases (MMP) 1 and 9 expression and increased activation of MAPK
and PI3K activity through ezrin in breast cancer, and by elevating the sol-
uble cat level/cat signaling through the p38 MAPK/GSK3 pathway in
glioblastoma [10,12]. On the other hand, C5aR/C5a signaling was
reported to raise the release of MMP from cancer cells – similarly to
PODXL1 – to induce PI3K/AKT activation and inhibit p21/pp21 expres-
sion, and even to exhibit immunomodulatory effects in facilitating cancer
metastasis by suppressing effector CD8(+) and CD4(+) Tcell responses
[25–27]. Collectively, this information implicates the presently studied
molecules as crucially determinant for metastasis, and for resultant poor
prognosis, in a wide range of tumors. However, these molecules have also
been reported as being independently significant in their biology. In this
study, we found the direct molecular connection between PODXL1 and
C5aR/C5a axis by demonstrating that PODXL1 is considered to be one
of the important binding partner with C5aR, which stabilizes C5aR and
recruits it to its functional site (cell membrane) on PDAC cells. Namely,
PODXL1 is considered to be essential to activation of C5aR, leading to
acquisition of cellular motility imparting invasive and metastatic properties
to PDAC cells (Figure 6E). This novel finding may provide a clearcut
explanation for the various earlier oncology studies on PODXL1 and
C5aR/C5a, although further investigation is necessary for the detailed
structure and function of the PODXL1C5aR complex, and for the mech-
anism of recruitment of the complex to the plasma membrane. Our exper-
iments also revealed the multifunctional aspects of PODXL1 appearing to
allow capture of multiple chemokine/cytokine receptors induced in the
tumor microenvironment. We suggest that PODXL1 plays a central role
in progression of diverse cancers by activating the soluble factors in
response to their unique tumor microenvironment. This notion is sup-
ported by earlier reports that the glycosylated form of PODXL1,
TRA160 antigen [22,28], was utilized as an important cellular marker
for iPS cells to confirm their fullreprogramming status [29], reflecting a
wide action permitting multipotent differentiation in response to diverse
stimuli.
In a recent trend, multiple oncology studies in tumor medicine have
emphasized the importance of the expulsion of cancer stem cells, as they
are strongly resistant to known anticancer treatments and hence are
sources for recurring malignancy. With that in mind it remains unclear
whether PODXL1expressing tumors contain cancer stemphenotype cells,
but the tumors may yet correlate highly with relapse and progression
specifically due to the diverse function of PODXL1/TRA160 [30] in
the microenvironment, as was demonstrated in this study. Our investiga-
tions, importantly, represent a framework for precision therapeutic control
of the PODXL1expressing cancer cell, so as to overcome intractable malig-
nancies such as PDACs.
Conclusions
In this study, we found novel crosstalk between the critical two tumor
regulators, PODXL1 and C5aR, in pancreatic cancer (PDAC) which sig-
nificantly contribute PDAC invasion/metastasis. Through their specific
interaction, PDAC acquired accelerated cellular motility and caused
aggressive metastasis which was corroborated by in vivo assays of xeno-
grafted model using PODXL1knockout PDAC cell in comparison with
the wild type cell. Furthermore, PODXL1 may be multifunctional because
it is capable of capturing various chemokine (cytokine) receptors, which
suggests diverse role of PODXL1 in the tumor microenvironment.
Figure 4. PODXL1 accelerates PDAC cellular motility by activating C5aR with triggering EMT. (A) IP assay demonstrated PODXL1 specifically bound
to C5aR. Endogenous expression of PODXL1 in the PODXL1-WT and the KO MiaPaCa-2 cells (left). Precipitates by anti-PODXL1 Ab probed with
anti-C5aR Ab showed PODXL1-C5aR binding not in the KO cells but in the WT cells (right). (B) Visualizing the alteration of C5aR intracellular
localization with or without PODXL1 by Fluoppi assay. Cellular localization of C5aR was examined on HeLa cotransfected with PODXL1-Ash and
C5aR-red compared with the cells transfected with C5aR-red alone (lower panel). Correct system behavior was confirmed by the PODXL1-Ash + CTTN-
red cotransfected cells (CTTN is a known binding partner of PODXL1) as a positive control (upper panel). Arrows indicated membrane localization of
fluorescent dots. (C) Loss of the cellular motility in the PODXL1-KO cells treated with C5a by invasion assay (Boyden chamber assay). Accelerated
motility of the PODXL1-WT MiaPaCa-2 in response to C5a (left), loss of the response in the PODXL1-KO cells (right). (D) Endogenous expression of
C5aR in the PODXL1-WT and the KO cells of MiaPaCa-2 or AsPC-1 by IF using confocal-laser scanning microscope. (E) Decreased expression of C5aR
in the PODXL1-KO PDAC cells in comparison with that in the WT cells (left). Marked shift of intracellular localization of C5aR demonstrated by IB for
the extracts between membrane fraction and cytosolic fraction from the PODXL1-WT and PODXL1-KO PDAC cells (right). Transferrin receptor and
CXADR were shown as positive control for membrane extract. (F) EMT triggered with C5a stimulation in the PODXL1-WT PDAC cells. Decreased
expression of E-Cadherin, upregulation of Snail and Vimentin in the WT cells only when stimulated with C5a by IB. Tubulin was shown as a control.
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Figure 5. C5aR/C5a axis is essential to cause liver metastasis of MiaPaCa-2 in vivo. (A) Administration protocol of the C5a-neutralizing Ab
(50 g/mouse/time) to the mice splenically injected with MiaPaCa-2 (1 106 cells). The mice splenically injected with MiaPaCa-2 had in total three
intravenous injections of the Ab, once per week, and were autopsied on the Day 30 (upper panel). Development of liver metastasis of implanted
MiaPaCa-2 cells with or without C5a Ab-treatment (lower panel). Attached Graphs showed average number of liver metastasis/mouse in the mice treated
with control IgG or those treated with anti-C5a Ab (n = 4/each group, means and s.d. of quadruplicate were shown). (B) IHC analyses of the metastatic
focus of MiaPaCa-2 in the mouse model. Liver isolated from the mice without treatment by anti-C5a Ab shown above was subjected to IHC analysis
detecting C5a, C5aR, and PODXL1 expression on metastatic focus. The bottom panel showed coexpression of PODXL1 (red) and Vimentin (green) on
an individual cancer cell by double IF.
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Figure 6. Endogenous expression of C5aR, PODXL1 and C5a on the PDAC patient tissues. (A) IHC staining of C5aR on the invasive nests of primary
PDAC tissues (two cases of PDAC patients). (B) Double IF showed membranous colocalization of PODXL1 (red) and C5aR (green) on the cancer nest
at the invasive front of human PDAC. (C) Coexpression of C5aR and PODXL1 on cancer cells of primary PDAC tissues and the liver metastasis of the
same patient. (D) Coexpression of C5aR and C5a at the liver metastatic focus of the PDAC patient. Note that non-neoplastic hepatocytes are also positive
for both. (E) Schematic representation of the specific interaction of PODXL1-C5aR/C5a axis in PDAC invasion/metastasis.
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